EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy

Omar Ragy iD, Wessam Abass, Durga Anil K Kanigicherla iD, Bethany Shinkins, Janine Bestall, Natalie King, Paul Brenchley, Alison Smith, Patrick Hamilton iD

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf012 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Omar Ragy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, UK. Hauptthemen laut MEDLINE: Receptors, Phospholipase A2, Glomerulonephritis, Membranous, Biomarkers, Autoantibodies. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Institute for Health and Care Research, UK Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The phospholipase A2 receptor antibody (PLA2R-Ab) test is a valuable first-line diagnostic tool for primary membranous nephropathy (MN), helping to identify PLA2R-related MN and potentially eliminating the need for a kidney biopsy in some individuals. By reducing the reliance on biopsies, the test streamlines diagnosis and improves patient care. However, determining the optimal PLA2R measurement method and cut-off is critical to maximizing the benefits of the test and minimizing any harms. A systematic review and meta-analysis were performed to evaluate serum- and urine-based biomarkers for distinguishing between PLA2R-related MN and non-PLA2R MN. Searches were conducted in databases including Medline, Embase, Cochrane Library, Scopus, Web of Science, International HTA Database and ClinicalTrials.gov. The methodology followed Cochrane-recommended guidelines for systematic reviews and meta-analyses, and the QUADAS-2 tool was utilized to assess the overall risk of bias. Ninety-one studies met the eligibility criteria for inclusion in the review. Of these, 38 studies reporting the accuracy of the PLA2R-Ab test using the EUROIMMUN enzyme-linked immunosorbent assay (ELISA) method and 27 using the EUROIMMUN immunofluorescence (IF) method were suitable for meta-analysis. The pooled sensitivity and specificity of EUROIMMUN ELISA at a cut-off value of 20 RU/mL were 0.64 [95% confidence interval (CI) 0.56–0.72] and 94.7% (95% CI 90.5–97.1%), respectively. The pooled sensitivity and specificity of EUROIMMUN IF at a threshold of 1:10 was 0.69 (95% CI 0.637–0.739) and 0.98 (95% CI 0.931–0.994), respectively. Risk of bias was higher for studies evaluating the IF compared with ELISA test. We also explored whether the timing of the index test had an impact on the pooled diagnostic accuracy results; no significant differences were found. By evaluating the specificity and sensitivity of EUROIMMUN ELISA PLA2R-Ab and IF, we demonstrate that at ELISA levels ≥20 RU/mL, alongside thorough secondary screening, a kidney biopsy may be unnecessary. However, lower or negative levels still warrant a biopsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Phospholipase A2Glomerulonephritis, MembranousBiomarkersAutoantibodiesNephrotic SyndromeHumansPrognosis

Stichwörter der Autor:innen

PLA2Rnon-invasive biomarkersprimary membranous nephropathysensitivity and specificity

Substanzen

Receptors, Phospholipase A2BiomarkersAutoantibodiesPLA2R1 protein, human

Autor:innen und Institutionen

  • Manchester Institute of Nephrology and Transplantation, Manchester University NHS Foundation Trust, Manchester, UK.
  • Division of Cardiovascular Sciences, University of Manchester, Manchester, UK.
  • Leeds Institute for Health Sciences, University of Leeds, Leeds, UK.
  • Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
  • Manchester Academic Health Science Centre, Research and Innovation, Manchester University NHS Foundation Trust, Manchester, UK.

ORCID-Profile: Omar Ragy, Durga Anil K Kanigicherla, Patrick Hamilton

Förderung

  • National Institute for Health and Care Research
  • UK Government

Zitieren

APA

Ragy, O., Abass, W., Kanigicherla, D. A. K., Shinkins, B., Bestall, J., King, N., Brenchley, P., Smith, A., & Hamilton, P. (2025). PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf012

Vancouver

Ragy O, Abass W, Kanigicherla DAK, Shinkins B, Bestall J, King N, et al. PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf012

BibTeX
@article{Ragy2025,
  author = {Ragy, Omar and Abass, Wessam and Kanigicherla, Durga Anil K and Shinkins, Bethany and Bestall, Janine and King, Natalie and Brenchley, Paul and Smith, Alison and Hamilton, Patrick},
  title = {PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf012}
}
Kostenlos starten →